IDEXX Labs Sees Higher FY22 Results - Quick Facts

Veterinary diagnostics provider IDEXX Laboratories, Inc. (IDXX), while announcing lower profit and higher revenues in its fourth quarter Wednesday, said it expects higher results in fiscal 2022.

The company expects earnings per share of $9.27 to $9.59, reflecting a targeted 50 - 100 basis points of comparable operating margin improvement.

The company expects full year 2022 revenue growth of 9 percent - 11 percent on a reported basis and 10 percent - 12 percent revenue growth on an organic basis.

In fiscal 2021, the company's earnings per share were $8.60 on revenues of $3.22 billion.

On average, analysts polled by Thomson Reuters expect earnings of $9.39 per share for the year on revenues of $3.54 billion. Analysts' estimates typically exclude special items.

The revenue view is supported by 10.5 percent - 12 percent reported growth, and 12 percent - 14 percent organic growth in CAG Diagnostics recurring revenues.

Jay Mazelsky, IDEXX's CEO, said, "IDEXX had a strong finish to an exceptional 2021, as busy veterinary customers responded positively to our highly differentiated diagnostic testing and information management platforms. ... As a Purpose-driven company focused on improving the health and well-being of pets, people and livestock, our outstanding results reflect the high levels of execution across the IDEXX organization through the challenges of the COVID-19 pandemic."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. may face production shortfall of as many as 6 million iPhone Pro units this year due to ongoing protests at its major China plant, Bloomberg reported citing a person familiar with assembly operations. Following the news, Apple shares were losing around 2.2 percent in pre-market activity on the Nasdaq. Despite fears of inflation, consumers spent $9.12 billion for online shopping during Black Friday, higher than in previous years, as per a report published by Adobe Analytics. During the 2022 holiday season, total estimated revenues are $209.7 billion, a growth of 2.5 percent from last year's recorded revenues of $205 billion. Weis Markets, Inc., a Mid Atlantic food retailer, has recalled 108 containers of Weis Quality Sea Salt Caramel Ripple Ice Cream citing possible presence of undeclared soy and coconut allergens, the U.S. Food and Drug Administration said. The recalled product comes in 48oz containers that says Weis Quality Sea Salt Caramel Ripple Ice Cream, while the lid says Weis Quality Caramel Caribou Ice Cream
Follow RTT